Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001829126-25-004013·Avenue Venture Opportunities Fund, L.P.
Schedule 13G ownership disclosure
CYTOSORBENTS CORP
Common Stock, par value $0.001 per share · CUSIP: 23283X206
Event date: 2024-06-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Avenue Venture Opportunities Fund, L.P.
Shares: 1,126,582.00 · Class: 1.7%
- Avenue Venture Opportunities Fund II, L.P.
Shares: 2,628,691.00 · Class: 4.0%
- Avenue Capital Management II, L.P.
Shares: 3,755,273.00 · Class: 5.7%
- Avenue Venture Opportunities Partners, LLC
Shares: 1,126,582.00 · Class: 1.7%
- Avenue Venture Opportunities Partners II, LLC
Shares: 2,628,691.00 · Class: 4.0%
- GL Venture Opportunities Partners, LLC
Shares: 1,126,582.00 · Class: 1.7%
- GL Venture Opportunities Partners II, LLC
Shares: 2,628,691.00 · Class: 4.0%
- Marc Lasry
Shares: 3,755,273.00 · Class: 5.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001829126-25-004013
- Form type
- SCHEDULE 13G
- Filer
- Avenue Venture Opportunities Fund, L.P.
- CIK
- CIK 1792691
- Filed
- May 28, 2025
- Reporting period
- Jun 26, 2024
- Description
- Schedule 13G beneficial ownership